An Extension of Janmahasatian's Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities
- 1 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 59 (9), 1161-1170
- https://doi.org/10.1007/s40262-020-00883-1
Abstract
Background Fat-free mass (FFM)-based dose scaling is increasingly being adopted in clinical pharmacology. Given the complexities with the measurement of FFM in clinical practice, choosing an appropriate equation for FFM is critical for accurate dose scaling. Janmahasatian's FFM model (FFMJan) has largely remained the preferred choice because of its mechanistic basis and good predictive properties. This model was, however, developed from a largely European cohort and has been shown to give biased predictions of FFM in Indian people. Objective The objective of this work was to derive an extended version of the FFMJan model (FFMExt) that accounts for the variation in body composition due to ethnicity, and to demonstrate its application by developing an extended FFM model in an Indian population (FFMExt,Ind). Methods The fundamental assumption of FFMJan model development was a linear relationship between bioimpedance and body mass index. In this extension to Janmahasatian's work, this assumption was extended to allow for potential non-linear relationships. While the original Z(Jan) model parameters were kept fixed, a set of body composition-related parameters psi{psi 1,psi 2,psi 3} were incorporated, where psi 1 and psi 2 were the ethnicity factors to the intercept and the linear coefficient, respectively, and psi 3 a non-linear exponent. The model was then applied to data arising from a south Indian population and the psi parameters were estimated by standard non-linear regression. The data were generated from a reference model for FFM for the Indian population, which was known to provide unbiased estimates for this population. Results The parameter estimates (%RSE) of the final FFMExt,Ind model were psi 1=0 (3.2%) for male patients, 0.70 (3.3%) for female patients, and psi 3=0.72 (12.4%). The final model predictions were in good agreement with the reference model predictions. Conclusions An FFMExt model has been achieved by extending the original FFMJan model assumptions to account for inter-ethnic differences in body composition. The extended model can be applied to any ethnic population by estimating a set of body composition-related parameters psi. This can be performed using bioimpedance data without the need for formal FFM measurements.This publication has 20 references indexed in Scilit:
- A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free MassClinical Pharmacokinetics, 2018
- Dexmedetomidine pharmacokinetics in the obeseEuropean Journal of Clinical Pharmacology, 2015
- How Should Obesity be Measured and How Should Anesthetic Drug Dosage be Calculated?Published by Springer Science and Business Media LLC ,2012
- Obesity and Allometric Scaling of PharmacokineticsClinical Pharmacokinetics, 2011
- Lean Body Weight Scalar for the Anesthetic Induction Dose of Propofol in Morbidly Obese SubjectsAnesthesia & Analgesia, 2011
- Pharmacokinetic considerations in the obeseBest Practice & Research Clinical Anaesthesiology, 2011
- Predictive Performance of the ‘Minto’ Remifentanil Pharmacokinetic Parameter Set in Morbidly Obese Patients Ensuing from a New Method for Calculating Lean Body MassClinical Pharmacokinetics, 2010
- Dosing in Obesity: A Simple Solution to a Big ProblemClinical Pharmacology & Therapeutics, 2007
- Pharmacokinetics in obese patientsContinuing Education in Anaesthesia Critical Care & Pain, 2004
- What is the best size descriptor to use for pharmacokinetic studies in the obese?British Journal of Clinical Pharmacology, 2004